June 19, 2012 | By Ryan McBride
Several biopharma players--including Emergent BioSolutions, GlaxoSmithKline and Novartis--landed on the winning end of contracts from the U.S. Department of Health and Human Services (HHS) to develop and churn out treatments against bioterror and pandemic threats. To fund the first phase of the effort, the HHS has committed $400 million.
The major endeavor strives to set up an infrastructure to rapidly advance from the development, to manufacturing of.. http://www.fiercebiotech.com/story/novartis-emergent-headline-400m-hhs-plan-combat-health-threats/2012-06-19
